JP2019518002A5 - - Google Patents

Download PDF

Info

Publication number
JP2019518002A5
JP2019518002A5 JP2018554348A JP2018554348A JP2019518002A5 JP 2019518002 A5 JP2019518002 A5 JP 2019518002A5 JP 2018554348 A JP2018554348 A JP 2018554348A JP 2018554348 A JP2018554348 A JP 2018554348A JP 2019518002 A5 JP2019518002 A5 JP 2019518002A5
Authority
JP
Japan
Prior art keywords
suspension
hids
raav
patient
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018554348A
Other languages
English (en)
Japanese (ja)
Other versions
JP7171439B2 (ja
JP2019518002A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/027770 external-priority patent/WO2017181113A1/en
Publication of JP2019518002A publication Critical patent/JP2019518002A/ja
Publication of JP2019518002A5 publication Critical patent/JP2019518002A5/ja
Priority to JP2022176178A priority Critical patent/JP2023011821A/ja
Application granted granted Critical
Publication of JP7171439B2 publication Critical patent/JP7171439B2/ja
Priority to JP2025138884A priority patent/JP2025170352A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018554348A 2016-04-15 2017-04-14 ムコ多糖症ii型を処置するための遺伝子療法 Active JP7171439B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022176178A JP2023011821A (ja) 2016-04-15 2022-11-02 ムコ多糖症ii型を処置するための遺伝子療法
JP2025138884A JP2025170352A (ja) 2016-04-15 2025-08-22 ムコ多糖症ii型を処置するための遺伝子療法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201662323194P 2016-04-15 2016-04-15
US62/323,194 2016-04-15
US201662330938P 2016-05-03 2016-05-03
US62/330,938 2016-05-03
US201662337163P 2016-05-16 2016-05-16
US62/337,163 2016-05-16
US201662367780P 2016-07-28 2016-07-28
US62/367,780 2016-07-28
US201762452494P 2017-01-31 2017-01-31
US62/452,494 2017-01-31
PCT/US2017/027770 WO2017181113A1 (en) 2016-04-15 2017-04-14 Gene therapy for treating mucopolysaccharidosis type ii

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022176178A Division JP2023011821A (ja) 2016-04-15 2022-11-02 ムコ多糖症ii型を処置するための遺伝子療法

Publications (3)

Publication Number Publication Date
JP2019518002A JP2019518002A (ja) 2019-06-27
JP2019518002A5 true JP2019518002A5 (https=) 2020-05-28
JP7171439B2 JP7171439B2 (ja) 2022-11-15

Family

ID=60042827

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018554348A Active JP7171439B2 (ja) 2016-04-15 2017-04-14 ムコ多糖症ii型を処置するための遺伝子療法
JP2022176178A Pending JP2023011821A (ja) 2016-04-15 2022-11-02 ムコ多糖症ii型を処置するための遺伝子療法
JP2025138884A Pending JP2025170352A (ja) 2016-04-15 2025-08-22 ムコ多糖症ii型を処置するための遺伝子療法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022176178A Pending JP2023011821A (ja) 2016-04-15 2022-11-02 ムコ多糖症ii型を処置するための遺伝子療法
JP2025138884A Pending JP2025170352A (ja) 2016-04-15 2025-08-22 ムコ多糖症ii型を処置するための遺伝子療法

Country Status (11)

Country Link
US (2) US11253612B2 (https=)
EP (1) EP3452104A1 (https=)
JP (3) JP7171439B2 (https=)
KR (3) KR20230125339A (https=)
AU (2) AU2017250298B2 (https=)
BR (1) BR112018071156A2 (https=)
CA (1) CA3019427A1 (https=)
IL (2) IL305449B2 (https=)
MA (1) MA44874A (https=)
SG (2) SG10201912761UA (https=)
WO (1) WO2017181113A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190139951A (ko) 2017-04-14 2019-12-18 리젠엑스바이오 인크. 인간 뉴런 또는 신경교 세포에 의해 생성된 재조합 인간 이두로네이트-2 설파타제(ids)를 이용한 뮤코다당증 ii형의 치료
KR102883778B1 (ko) * 2017-09-22 2025-11-12 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Ii형 점액다당류증의 치료를 위한 유전자 요법
CR20200129A (es) 2017-10-02 2020-08-22 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas
WO2019094253A1 (en) * 2017-11-08 2019-05-16 Avexis Inc. Means and method for preparing viral vectors and uses of same
EP3768695A4 (en) 2018-02-27 2022-04-06 The Trustees of the University of Pennsylvania NOVEL ADENO-ASSOCIATED VIRUS (AAV) VECTORS, AAV VECTORS WITH REDUCED CAPSIID DEAMIDATION AND USES THEREOF
EP3801638A1 (en) 2018-06-08 2021-04-14 Novartis AG Cell-based assay for measuring drug product potency
BR112021009370A2 (pt) * 2018-11-14 2021-08-17 Regenxbio Inc. método de tratamento da doença de batten cln2, composição farmacêutica e kit
AU2020401116A1 (en) 2019-12-10 2022-07-21 Takeda Pharmaceutical Company Limited Adeno associated virus vectors for the treatment of Hunter disease
BR112022015183A2 (pt) * 2020-01-29 2022-12-20 Regenxbio Inc Método para tratamento de um sujeito humano diagnosticado com mucopolissacaridose tipo ii (mps ii)
IL296986A (en) * 2020-04-06 2022-12-01 Homology Medicines Inc Adeno-associated virus preparations for ids gene transfer and methods of use thereof
MX2022014258A (es) 2020-05-12 2023-02-22 Univ Pennsylvania Composiciones para la reducción específica de un fármaco de la expresión de transgén.
WO2022040530A2 (en) * 2020-08-21 2022-02-24 Capsida, Inc. Virus compositions for treating mucopolysaccharidosis ii
EP4291249A2 (en) 2021-02-10 2023-12-20 RegenxBio Inc. Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids)
WO2022212616A1 (en) * 2021-04-01 2022-10-06 The University Of North Carolina At Chapel Hill Aav-ids vectors for treatment of mucopolysaccharidosis ii
CN115820740A (zh) * 2021-09-16 2023-03-21 北京锦篮基因科技有限公司 用于治疗ⅱ型粘多糖贮积症的重组腺相关病毒载体及其应用
US20250295807A1 (en) 2021-11-15 2025-09-25 The Trustees Of The University Of Pennsylvania Compositions for drg-specific reduction of transgene expression
US20250115903A1 (en) * 2022-01-17 2025-04-10 Ryan T. Gill Compositions and methods for editing genomes
WO2025075963A1 (en) * 2023-10-02 2025-04-10 Regenxbio Inc. Methods and formulations for treating mucopolysaccharidosis ii-associated hearing loss with recombinant human iduronate-2-sulfatase

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407061B1 (en) 1989-12-05 2002-06-18 Chiron Corporation Method for administering insulin-like growth factor to the brain
CA2070823C (en) 1989-12-05 1999-01-12 William H. Ii Frey Neurologic agents for nasal administration to the brain
US5624898A (en) 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
FR2716893B1 (fr) * 1994-03-03 1996-04-12 Rhone Poulenc Rorer Sa Virus recombinants, leur préparation et leur utilisation thérapeutique.
US6190659B1 (en) 1996-09-17 2001-02-20 The Rockefeller University Bacterial plasmin binding protein and methods of use thereof
AU8672198A (en) 1997-07-31 1999-02-22 Chiron Corporation Method enabling readministration of aav vector via immunosuppression of host
WO1999061066A2 (en) 1998-05-27 1999-12-02 Avigen, Inc. Convection-enhanced delivery of aav vectors
ES2252993T3 (es) 1998-12-09 2006-05-16 Chiron Corporation Administracion de agentes neurotroficos al sistema nervioso central.
US7273618B2 (en) 1998-12-09 2007-09-25 Chiron Corporation Method for administering agents to the central nervous system
EP1135105B1 (en) 1998-12-09 2005-03-02 Chiron Corporation Use of a neurologic agent for the manufacture of a medicament for the treatment of a central nervous system disorder
CA2379166C (en) 1999-08-09 2013-03-26 Targeted Genetics Corporation Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs
US6569661B1 (en) 1999-11-12 2003-05-27 Biomarin Pharmaceutical Inc. Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
US6585971B1 (en) 1999-11-12 2003-07-01 Harbor-Ucla Research And Education Institute Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating disease caused by deficiencies thereof
US6582692B1 (en) 1999-11-17 2003-06-24 Avigen, Inc. Recombinant adeno-associated virus virions for the treatment of lysosomal disorders
WO2001041782A2 (en) 1999-12-09 2001-06-14 Chiron Corporation Method for administering a cytokine to the central nervous system and the lymphatic system
US7084126B1 (en) 2000-05-01 2006-08-01 Healthpartners Research Foundation Methods and compositions for enhancing cellular function through protection of tissue components
US20040204379A1 (en) 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
EP2767291B1 (en) 2000-07-18 2016-09-14 Duke University Treatment of glycogen storage disease type II
US20020014242A1 (en) 2000-07-31 2002-02-07 Abraham Scaria Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products
US20020082215A1 (en) 2000-10-13 2002-06-27 Chiron Corporation Method for treating ischemic events affecting the central nervous system
US20020169102A1 (en) 2001-04-03 2002-11-14 Frey William H. Intranasal delivery of agents for regulating development of implanted cells in the CNS
WO2002086105A1 (en) 2001-04-20 2002-10-31 Chiron Corporation Delivery of polynucleotide agents to the central nervous sysstem
MX359371B (es) 2001-11-13 2018-09-25 Univ Pennsylvania Un metodo para detectar y/o identificar secuencias del virus adeno-asociado y aislamiento de secuencias novedosas identificadas de ese modo.
PT1453547T (pt) 2001-12-17 2016-12-28 Univ Pennsylvania Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas
US20070004743A1 (en) 2002-02-25 2007-01-04 Xiao Linda L Intranasal administration of mc4-r agonists
US7485314B2 (en) 2002-05-06 2009-02-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Induction of antigen specific immunologic tolerance
AU2003302724A1 (en) 2002-08-13 2004-07-09 Mcivor, Scott, R. Methods of using vectors to treat metabolic disorders
US8512710B2 (en) 2002-11-22 2013-08-20 Ansun Biopharma, Inc. Class of therapeutic protein based molecules
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
EP2345731B1 (en) 2003-09-30 2015-10-21 The Trustees of the University of Pennsylvania Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof
US8071364B2 (en) 2003-12-24 2011-12-06 Transgenrx, Inc. Gene therapy using transposon-based vectors
US7618615B2 (en) 2004-08-13 2009-11-17 Healthpartners Research Foundation Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia
US7776312B2 (en) 2004-08-13 2010-08-17 Healthpartners Research Foundation Method of treating Alzheimer's disease comprising administering deferoxamine (DFO) to the upper one-third of the nasal cavity
US20060188496A1 (en) 2005-02-23 2006-08-24 Hanne Bentz Intranasal administration of active agents to the central nervous system
US20090136505A1 (en) 2005-02-23 2009-05-28 Johanna Bentz Intranasal Administration of Active Agents to the Central Nervous System
ES2525067T3 (es) 2005-04-07 2014-12-17 The Trustees Of The University Of Pennsylvania Método de incremento de la función de un vector de AAV
JP4495210B2 (ja) 2005-06-09 2010-06-30 パナソニック株式会社 振幅誤差補償装置及び直交度誤差補償装置
JP5276982B2 (ja) 2005-08-26 2013-08-28 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ オキシトシンの投与による頭痛の処置のための方法
AR059371A1 (es) 2006-02-08 2008-03-26 Genzyme Corp Terapia genica para la enfermedad de niemann-pick tipo a
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
US8153604B2 (en) 2006-04-24 2012-04-10 Geron Corporation CNS-tumor treatment method and composition
EP1915986A1 (en) 2006-10-23 2008-04-30 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Lipid growth factor formulations
EP2132309A4 (en) 2007-02-23 2011-01-05 Univ Florida COMPOSITIONS AND METHODS OF TREATING GLYCOLOGICAL MEMORY DISEASES
ES2635726T3 (es) 2007-06-06 2017-10-04 Genzyme Corporation Terapia génica para enfermedades de almacenamiento lisosómico
EP2152240A4 (en) 2007-06-08 2012-05-09 Healthpartners Res Foundation PHARMACEUTICAL COMPOSITIONS AND METHOD FOR REINFORCED TARGETING OF THERAPEUTIC COMPOUNDS TO THE CENTRAL NERVOUS SYSTEM
US8283160B2 (en) 2007-09-11 2012-10-09 Frey Ii William H Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system
EP2058401A1 (en) 2007-10-05 2009-05-13 Genethon Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
WO2009075815A1 (en) 2007-12-07 2009-06-18 Duke University Immunomodulating gene therapy
US9265843B2 (en) 2008-03-27 2016-02-23 The Ohio State University Treatment of metabolic-related disorders using hypothalamic gene transfer of BDNF and compositions therefor
US9415121B2 (en) 2008-12-19 2016-08-16 Nationwide Children's Hospital Delivery of MECP2 polynucleotide using recombinant AAV9
US11219696B2 (en) 2008-12-19 2022-01-11 Nationwide Children's Hospital Delivery of polynucleotides using recombinant AAV9
WO2010071832A1 (en) 2008-12-19 2010-06-24 Nationwide Children's Hospital Delivery of polynucleotides across the blood brain barrier using recombinant aav9
US7989502B2 (en) 2009-02-06 2011-08-02 Sri International Intranasal delivery of modafinil
WO2010093784A2 (en) 2009-02-11 2010-08-19 The University Of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
US20110070241A1 (en) 2009-06-30 2011-03-24 Duke University Methods for modulating immune responses to aav gene therapy vectors
US8622993B2 (en) 2009-12-18 2014-01-07 Healthpartners Research Foundation Device and method for delivering therapeutic substances to the maxillary sinus of a patient
WO2011126808A2 (en) 2010-03-29 2011-10-13 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
EP2561073B1 (en) 2010-04-23 2016-08-24 University of Massachusetts Cns targeting aav vectors and methods of use thereof
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
EP2394667A1 (en) 2010-06-10 2011-12-14 Laboratorios Del Dr. Esteve, S.A. Vectors and sequences for the treatment of diseases
LT2588130T (lt) 2010-06-25 2016-12-12 Shire Human Genetic Therapies, Inc. Terapinės priemonės pristatymas cns
PT3103469T (pt) 2010-06-25 2021-03-04 Shire Human Genetic Therapies Administração de agentes terapêuticos no snc
JP6073783B2 (ja) 2010-06-25 2017-02-01 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド ヘパランn−スルファターゼのcns送達のための方法および組成物
KR20230159646A (ko) 2010-06-25 2023-11-21 샤이어 휴먼 지네틱 테라피즈 인크. 이듀로네이트-2-설파타제의 cns 전달을 위한 방법들 및 조성물들
WO2012101671A1 (en) * 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
WO2012109570A1 (en) 2011-02-10 2012-08-16 The University Of North Carolina At Chapel Hill Viral vectors with modified transduction profiles and methods of making and using the same
TR201908020T4 (tr) 2011-02-17 2019-06-21 Univ Pennsylvania Doku özgüllüğünü değiştirmek ve aav9-aracılı gen transferini geliştirmek için bileşimler ve yöntemler.
WO2012135857A1 (en) 2011-03-31 2012-10-04 University Of Iowa Research Foundation Methods and compositions for treating brain diseases
US10196636B2 (en) 2011-04-21 2019-02-05 Nationwide Children's Hospital, Inc. Recombinant virus products and methods for inhibition of expression of myotilin
WO2012145597A2 (en) 2011-04-21 2012-10-26 Nationwide Children's Hospital, Inc. Recombinant virus products and methods for inhibition of expression of myotilin
US8609088B2 (en) 2011-05-10 2013-12-17 Regents Of The University Of Minnesota Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
EP2709670A4 (en) 2011-05-18 2015-01-21 Childrens Hosp Medical Center TARGETED TRANSFER OF PROTEINS OVER THE BLOOD BRAIN BARRIER
US20130039888A1 (en) 2011-06-08 2013-02-14 Nationwide Children's Hospital Inc. Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
EP2736539B1 (en) 2011-07-25 2017-08-23 Nationwide Children's Hospital, Inc. Recombinant virus products and methods for inhibition of expression of dux4
SG10201510106PA (en) 2011-10-12 2016-01-28 Synageva Biopharma Corp Recombinant human naglu protein and uses thereof
US9821149B2 (en) 2011-10-14 2017-11-21 Healthpartners Research & Education Methods for using ultrasound for enhancing efficiency and targeting of intranasal administration of therapeutic compounds to the central nervous system
AU2012346448B2 (en) 2011-12-02 2017-09-14 Armagen, Inc. Methods and compositions for increasing arylsulfatase A activity in the CNS
JP6188728B2 (ja) 2012-02-07 2017-08-30 グローバル・バイオ・セラピューティクス・インコーポレイテッドGlobal Bio Therapeutics,Inc. 核酸送達の区画化方法ならびにその組成物および使用
US20150182637A1 (en) 2012-06-21 2015-07-02 Association Institut De Myologie Widespread gene delivery of gene therapy vectors
AU2013296425B2 (en) 2012-08-01 2018-06-07 Nationwide Children's Hospital Intrathecal delivery of recombinant adeno-associated virus 9
US12024568B2 (en) 2012-09-13 2024-07-02 Cornell University Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies
ES2729997T3 (es) 2012-11-27 2019-11-07 Biomarin Pharm Inc Proteínas de fusión terapéuticas dirigidas de enzima lisosómica y usos de las mismas
WO2014125647A1 (ja) 2013-02-18 2014-08-21 富士通オプティカルコンポーネンツ株式会社 光受信装置
AU2014235096B2 (en) 2013-03-15 2020-03-19 The Trustees Of The University Of Pennsylvania Compositions and methods for treating MPSI
MX388221B (es) 2013-04-20 2025-03-19 Res Institute At Nationwide Children´S Hospital ADMINISTRACIÓN DE VIRUS ADENO-ASOCIADO RECOMBINANTE DE CONSTRUCCIONES DE POLINUCLÉOTIDOS U7snRNA DIRIGIDA AL EXÓN 2.
MX380973B (es) 2013-05-01 2025-03-12 Genzyme Corp Composiciones y metodos para tratar la atrofia muscular espinal.
CN115120746A (zh) 2013-05-15 2022-09-30 明尼苏达大学董事会 腺相关病毒介导的基因向中枢神经系统转移
EP3024497B1 (en) 2013-07-26 2021-01-13 University of Iowa Research Foundation Methods and compositions for treating brain diseases
SI3702466T1 (sl) 2013-08-27 2023-04-28 Research Institute At Nationwide Children's Hospital Proizvodi in postopki za zdravljenje amiotrofične lateralne skleroze
ES2739288T3 (es) 2013-09-13 2020-01-30 California Inst Of Techn Recuperación selectiva
CN105745326A (zh) 2013-10-24 2016-07-06 优尼科Ip有限公司 用于基因治疗神经疾病的aav-5假型载体
EP3134113A4 (en) 2014-04-25 2017-11-29 University of Florida Research Foundation, Inc. Methods of permitting a subject to receive multiple doses of recombinant adeno-associated virus
WO2015164723A1 (en) * 2014-04-25 2015-10-29 The Trustees Of The University Of Pennsylvania Methods and compositions for treating metastatic breast cancer and other cancers in the brain
AU2015320694B2 (en) 2014-09-24 2021-11-11 City Of Hope Adeno-associated virus vector variants for high efficiency genome editing and methods thereof
WO2016100575A1 (en) 2014-12-16 2016-06-23 Board Of Regents Of The University Of Nebraska Gene therapy for juvenile batten disease
HK1256341A1 (zh) 2015-05-15 2019-09-20 明尼苏达大学董事会 用於治疗性递送到中枢神经系统的腺相关物
EP3101125A1 (en) 2015-06-05 2016-12-07 Laboratorios Del Dr. Esteve, S.A. Adenoassociated virus vectors for the treatment of mucopolysaccharidoses
EP3411484B1 (en) 2016-02-05 2023-10-04 Emory University Injection of single-stranded or self-complementary adeno-associated virus 9 into the cerebrospinal fluid
US10561894B2 (en) 2016-03-18 2020-02-18 Icon Health & Fitness, Inc. Treadmill with removable supports
JP2020500928A (ja) 2016-11-15 2020-01-16 リジェネクスバイオ インコーポレイテッド Mpsiおよびmpsiiならびに他の神経障害において神経機能を改善するための方法
KR102883778B1 (ko) * 2017-09-22 2025-11-12 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Ii형 점액다당류증의 치료를 위한 유전자 요법

Similar Documents

Publication Publication Date Title
JP2019518002A5 (https=)
US11896652B2 (en) Modified factor IX, and compositions, methods and uses for gene transfer to cells, organs, and tissues
US20240000886A1 (en) Compositions and Methods for Treating Spinal Muscular Atrophy
JP2019512005A5 (https=)
US12338450B2 (en) Gene therapy constructs for treating Wilson disease
US12171843B2 (en) Hybrid regulatory elements
JP7082050B2 (ja) 脊髄性筋萎縮症の処置において有用なアデノ-関連ウイルスベクター
JP6978407B2 (ja) Glp−1及び代謝性疾患を治療するための組成物におけるその使用
HK1249548A1 (zh) 用於无脉络膜的基因疗法的aav载体
JP7061067B2 (ja) クリグラー・ナジャー症候群の処置のための組成物
JP2019533992A (ja) 酸性αグルコシダーゼ変異体及びその使用
JP7106534B2 (ja) メチル-cpg結合タンパク質2をコードする組換えアデノ随伴ウイルスの髄腔内送達
JP7548899B2 (ja) 糖原病iiiの処置のためのミニgde
CN110809626A (zh) 磺酰胺酶(sgsh)变体、载体、组合物以及用于治疗iiia型粘多糖病(mps iiia)的方法和用途
JP2018501791A (ja) 改変g6pcをコードするアデノ随伴ウイルスベクターおよびその使用
CN113574176A (zh) 腺相关病毒对cln6多核苷酸的递送
CN119487078A (zh) 编码胰岛素融合蛋白的病毒载体基因组
CN113891712A (zh) 用于晚期婴儿神经元蜡样脂褐质沉积症2型的aav载体治疗方法
JP7674391B2 (ja) グルコース-6-ホスファターゼ(G6Pase-a)をコードする遺伝子治療用ベクター
WO2024060463A1 (zh) 改进的人凝血因子viii基因表达盒及其应用
CN116033915A (zh) 用于治疗gm1神经节苷脂贮积症及其它病症的组合物和方法
BR112017027956B1 (pt) Vetores de vírus adenoassociado recombinante, uso e método de produção dos mesmos, e composição farmacêutica